Japanese industrial and technology conglomerate Nitto Denko Corporation and Bristol-Myers Squibb (BMS) have entered into an agreement granting the latter exclusive worldwide rights for the development and commercialization of Nitto technological research.
Nitto’s investigational siRNA molecules target heat shock protein 47 (HSP47) in vitamin A containing formulations, which includes Nitto’s lead asset, ND-L02-s0201, currently being studied for the treatment of advanced liver fibrosis.
The agreement grants BMS the option to receive exclusive licences to Nitto’s siRNA therapy for the treatment of lung fibrosis and other organ fibrosis. The agreement is subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As part of the arrangement, BMS will pay US$100 million to Nitto. Nitto will also be eligible to receive subsequent clinical and regulatory milestone payments, royalties, sales-based milestone payments, as well as option exercise payments.
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
